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Background: The beneﬁ  cial effects of statins were unequivocally demonstrated in the 
Scandinavian Simvastatin Survival Study (4S) in 1994, leading to an increase in the use of lipid-
lowering drugs. However, to what extent this translates into serum cholesterol levels in a real-life 
setting has not been systematically investigated.
Objective: To estimate secular trends from 1994 to 2002 in blood lipid levels among unselected 
younger patients after a ﬁ  rst acute myocardial infarction (AMI).
Method: Descriptive single centre study using consecutive data collection in 781 patients 
(aged 65 years) hospitalized with a ﬁ  rst AMI during the period 1994–2002.
Results: From 1994–2002, the use of lipid-lowering drugs increased from 10% to 94% for men 
and from 23% to 90% for women. In 1994, the mean serum cholesterol levels were 6.53 mmol/l 
in men and 6.32 mmol/l in women, decreasing to 4.31 mmol/l and 5.13 mmol/l in men and 
women, respectively, in 2002. Still, only 56% of the men and 35% of the women had total 
serum cholesterol levels 4.5 mmol/l in 2002.
Conclusion: Despite a marked increase in lipid-lowering drug treatment in which there was an 
increase from about 10% in 1994 to more than 90% in 2002, current target levels of 4.5 mmol/l 
for serum cholesterol were not achieved in a signiﬁ  cant proportion of post-AMI patients.
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Introduction
Cardiovascular risk factors and prevention
Low-density lipoprotein cholesterol (LDL) concentration in serum is well established 
as one of the most important risk factors of coronary heart disease (CHD) and 
much research has been devoted to lipid-lowering therapies and diet modiﬁ  cations 
(Anonymous 1975, 1984a, 1984b; Brensike et al 1984). The relation between serum 
cholesterol levels and CHD is strong and curvilinear with no obvious lower threshold 
(Shekelle et al 1981; Pekkanen et al 1990; Law and Wald 1994). Even relatively small 
changes in serum cholesterol are closely related to CHD incidence and mortality. 
Lowering serum cholesterol by 0.6 mmol/l (10%) has been estimated to decrease the 
risk of CHD by 50% at the age of 40, and by 20% at 70 years. The full effect in risk 
reduction of decreasing serum cholesterol concentration is reported to be achieved 
within 5 years (Law et al 1994a, 1994b).
After the publication of several secondary prevention studies (Anonymous 
1975, 1980, 1984, 1984a, 1984b, 1987; Levy et al 1984; Brensike et al 1984; 
Blankenhorn et al 1987; Buchwald et al 1990; Watts et al 1992), lipid lowering 
by pharmacological agents is now standard therapy after an acute myocardial 
infarction (AMI). The Scandinavian Simvastatin Survival Study (4S) (Anonymous 
1994) was the ﬁ  rst, however, to demonstrate unequivocally the beneﬁ  cial effects Vascular Health and Risk Management 2007:3(6) 1046
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of lipid-lowering drugs in patients with CHD. Yet, how 
this has inﬂ  uenced lipid levels in unselected post-AMI 
patients has not been systematically explored. Therefore, 
the aim of this single-centre study was to describe among 
younger men and women with a ﬁ  rst AMI changes in 
pharmacological treatment with lipid-lowering drugs 
between 1994 and 2002, to quantify ensuing changes in 
mean serum concentrations of cholesterol and triglycer-
ides, and to estimate the proportion of patients who meet 
current European target levels for serum total cholesterol 
(De Backer et al 2003).
Methods
Patients for this study were consecutively included among 
patients discharged from the Coronary Care Unit (CCU) 
or step-down unit at the Sahlgrenska University Hospital/
Östra, Sweden. The catchment’s area of the Sahlgrenska 
University Hospital/Östra is the northern and eastern parts 
of Göteborg, with a population of 250,000. Since 1994, all 
patients under 65 years of age with a ﬁ  rst AMI were sched-
uled for a structured nurse-led follow-up visit 3 months after 
discharge. During the period 1994 to 2002, 952 patients were 
discharged alive from hospital with a discharge diagnosis 
of a ﬁ  rst myocardial infarction deﬁ  ned as typical symptoms 
and either typical ECG changes and/or increased levels of 
creatin-kinaseMB subunit mass concentration (1994–2001  
15 μg/l, from 2002 10 μg/l). Four patients died before they 
could be investigated, the medical condition of 8 patients 
precluded the follow-up visit and 16 patients had their visit 
in another area. One hundred forty-three patients were either 
not admitted to the coronary care unit and were therefore not 
scheduled for routine follow-up, or had a late follow-up with 
no systematic collection of data and were thus excluded. After 
these exclusions, 781 patients (607 men, 174 women) were 
available for the present investigation. All patients were rou-
tinely offered dietary counseling by nurses and dieticians in 
group sessions using essentially the same methods throughout 
the study period. At the 3-month follow-up, anthropometric 
measurements, including blood samples, were performed 
and information on previous diabetes, hypertension and 
smoking were recorded in a standardized protocol. The study 
protocol was approved by the Ethics committee of Göteborg 
University.
Follow-up visit
At follow-up 3 months after the myocardial infarction, blood 
samples for serum cholesterol and serum triglycerides were 
drawn after an overnight fast. Use of any lipid-lowering 
drug and dosage was recorded, as were data on smoking, 
diabetes and hypertension. Body weight was measured on 
a lever balance to the nearest 0.1 kg while the patient was 
wearing indoor clothing. Height was recorded to the near-
est centimetre. Body mass index (BMI, weight in kg/height 
in m2) was used as an index of relative weight and over-
weight/obesity.
Deﬁ  nitions
Hypertension was deﬁ  ned as diagnosed by a physician 
before hospitalization. Diabetes was deﬁ  ned as diagnosed 
by a physician before or during hospitalization. Data on 
smoking habits at the time of hospitalization and at the fol-
low-up visit were self-reported and/or from hospital records. 
Total cholesterol concentration and serum triglyceride 
concentration were measured at the 3-month follow-up or 
at a later visit (maximum 6 months after the AMI). Blood 
samples were drawn from an antecubital vein and fasting 
serum cholesterol and triglyceride measurements were 
determined according to standard laboratory procedures. 
Since 1993, serum cholesterol has been analyzed according 
to Boehringer Mannheim (cat. no. 701912). This method is 
the standard method of the Laboratory of Clinical Chemistry 
(certiﬁ  ed laboratory) at Göteborg University and remained 
constant through the study period. Target levels for total 
serum cholesterol were deﬁ  ned as 4.5 mmol/l accord-
ing to the current European Society of Cardiology (ESC) 
guidelines (De Backer et al 2003).
Statistical methods
The SPSS statistical package (version 11.0) was used for all 
statistical analyses. Background data were divided into three 
3-year periods: 1994–1996, 1997–1999, and 2000–2002. The 
results are shown as means and standard deviations (SD) 
for serum cholesterol, serum triglycerides and percentage 
treated with lipid-lowering drugs each 3-year period from 
1994–2002. EpiInfo was used for statistical analysis of lin-
ear trends over the years 1994–2002. p-values  0.05 were 
considered signiﬁ  cant.
Results
Risk factors at baseline
Patient characteristics are shown in Table 1. Mean age for 
men was 54.0 (SD 7.65) years and for women 55.7 (SD 
7.29) years. Fifty-six and 59% of the men and women, 
respectively, were smokers before their AMI. At follow-up, 
24% of the men and 27% of the women were still smoking. 
One in ﬁ  ve patients had diabetes, with no gender differences. Vascular Health and Risk Management 2007:3(6) 1047
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More women than men had a previous diagnosis of hyper-
tension (43% and 25% in women and men, respectively). 
More than half of the women and two thirds of the men were 
overweight or obese.
Lipid-lowering drugs and lipid levels
The proportion treated with lipid-lowering drugs increased 
substantially during the investigated period in both genders 
(Figure 1). In 1994, 10% of all men and 23% of all women 
were treated with lipid-lowering drugs. In 2002, the pro-
portion of patients treated with lipid-lowering drugs had 
increased to approximately 90% in both men and women. 
The linear trend over the period was signiﬁ  cant in both men 
and women (p  0.0001). In 1994, the mean total serum 
cholesterol was 6.53 (SD 1.27) and 6.32 mmol/l (SD 1.34) 
in men and women, respectively. During the study period, 
the mean serum cholesterol levels decreased steadily and, 
in 2002, the mean serum cholesterol in men and women, 
respectively, was 4.31 (SD 1.16) and 5.13 mmol/l (SD 
1.47) (Figure 2). The linear trend was signiﬁ  cant for both 
genders (p  0.0001). Mean serum triglycerides also 
decreased during the years 1994 to 2002. In 1994, the mean 
serum triglyceride levels were 2.55 mmol/l (SD 1.58) in 
men and 2.16 mmol/l (SD 1.11) in women, and in 2002 
1.72 mmol/l (SD 0.81) and 1.77 mmol/l (SD 1.13) in men 
and women, respectively (Figure 3) (p for linear trend over 
time was 0.0001 in men and 0.05 in women). In 2002, 
65% of the men and 50% of the women had total serum 
cholesterol levels 5.0 mmol/l. If target levels for serum 
total cholesterol instead were deﬁ  ned as 4.5 mmmol/l), 
Table 1 Baseline characteristics for 781 patients, 607 (78%) men and 174 (22%) women, with a ﬁ  rst myocardial infarction
   1994–19961 1997–19992 2000–20023 Total
Age, n, mean (SD)  Men  54.1 (8.32)  53.3 (6.98)  54.4 (7.43)  54.0 (7.65)
  Women  55.9 (7.07)  54.9 (7.80)  56.1 (7.09)  55.7 (7.29)
  Total  54.5 (8.11)  53.7 (7.20)  54.8 (7.40)  54.3 (7.60)
BMI, mean (SD)  Men  27.7 (3.70)  28.3 (3.56)  27.5 (3.96)  27.8 (3.76)
  Women  27.5 (4.20)  29.0 (6.45)  27.8 (4.34)  28.1 (5.09)
  Total  27.6 (3.80)  28.4 (4.41)  27.6 (4.05)  27.9 (4.09)
BMI 25–29.9% (n)  Men  55 (120)  52 (92)  53 (104)  53 (316)
  Women  38 (20)  40 (22)  35 (22)  37 (64)
  Total  51 (140)  49 (114)  48 (126)  50 (380)
BMI 30% (n)  Men  24 (52)  27 (47)  22 (43)  24 (142)
  Women  30 (16)  33 (18)  33 (21)  32 (55)
  Total  25 (68)  28 (65)  25 (64)  26 (197)
Diabetes % (n)  Men  21 (48)  12 (21)  21 (42)  18 (111)
  Women  19 (10)  18 (10)  23 (15)  20 (35)
  Total  21 (58)  13 (31)  21 (57)  19 (146)
Hypertension % (n)  Men  24 (55)  26 (46)  25 (52)  25 (153)
  Women  44 (24)  42 (23)  42 (27)  43 (74)
  Total  29 (79)  30 (69)  29 (79)  29 (227)
Smoking % (n)  Men  60 (134)  57 (100)  53 (108)  56 (342)
  Women  59 (32)  62 (34)  55 (36)  59 (102)
  Total  60 (166)  58 (134)  53 (144)  57 (444)
At follow-up       
Smoking % (n)  Men  29 (66)  22 (39)  21 (43)  24 (148)
  Women  30 (16)  33 (18)  20 (13)  27 (47)
  Total  29 (82)  25 (57)  21 (56)  25 (195)
Serum cholesterol  Men  6.18 (1.29)  5.52 (1.12)  4.58 (1.14)  5.46 (1.36)
mmol/l, mean (SD)  Women  6.11 (1.26)  5.56 (1.24)  4.97 (1.28)  5.51 (1.34)
  Total  6.16 (1.28)  5.53 (1.15)  4.68 (1.18)  5.47 (1.36)
Serum triglycerides   Men  2.61 (1.91)  2.34 (1.40)  1.82 (0.97)  2.27 (1.53)
mmol/l, mean (SD)  Women  2.24 (1.75)  1.97 (1.04)  1.82 (1.02)  2.00 (1.30)
  Total  2.54 (1.88)  2.25 (1.32)  1.82 (1.00)  2.20 (1.49)
Lipid lowering   Men  18 (41)  46 (81)  73 (151)  45 (273)
medication % (n)  Women  24 (13)  40 (22)  86 (56)  52 (91)
  Total  19 (54)  44 (103)  77 (207)  47 (364)
Notes: 11994–1996 225 men and 54 women.
21997–1999 177 men and 55 women.
32000–2002 205 men and 65 women.Vascular Health and Risk Management 2007:3(6) 1048
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these levels were achieved in 56% of the cases in men and 
35% in women.
Discussion
The results from the 4S study, the ﬁ  rst study to demonstrate 
unequivocally the beneﬁ  ts of statin therapy in CHD patients, 
were presented in 1994 (Anonymous 1994). In response to 
the results of the study and other, ensuing lipid-lowering 
secondary prevention trials treatment with statins in order 
to improve patient outcome is now standard practice in 
CHD patients. The present study provided an opportunity 
to investigate the implementation of this landmark study. 
Over the 9-year period between 1994 and 2002, the use 
of lipid-lowering medication (eg, statins) increased from 
a low to a markedly high level in younger patients with 
a ﬁ  rst AMI, with a concomitant decrease in lipid levels. 
Despite the huge increase in lipid-lowering drug treatment, 
in which there was an increase from about 10% in 1994 to 
90% in 2002, current target levels of 4.5 mmol/l for serum 
cholesterol were not achieved in a signiﬁ  cant proportion of 
these patients. The results from the study correspond with 
those from the Swedish centre (Malmö) in the Euroaspire II 
study (Anonymous 2001) except for the higher percentage 
treated with a statin in our study (90% compared with 74% 
in CHD patients in Euroaspire II). In the Euroaspire II sur-
vey 65% of the patients reached target levels (5 mmol/l) 
for serum total cholesterol; in our study 62% reached these 
same target levels.
In 2002, the Heart Protection Study (HPS) (HPSCG 
2002) established that lowering cholesterol with 40 mg 
simvastatin daily substantially reduced the incidence of 
major vascular events in high-risk individuals, irrespective 
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Figure 1 Percent of men and women with lipid-lowering medication at 3-months follow-up after hospitalization for ﬁ  rst myocardial infarction during 1994–2002.
Figure 2 Mean serum cholesterol in men and women at 3-months follow-up after hospitalization for ﬁ  rst myocardial infarction during 1994–2002.
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of initial cholesterol level. Following the results in the trial, 
patients are now routinely treated with 40 mg simvastatin, 
regardless of initial cholesterol concentrations. Among the 
98 patients discharged in 2002, 8.1% (n = 8), however, had 
no lipid-lowering treatment due to side-effects (n = 2), liver 
disease (n = 4) or unknown reasons (n = 2).
In the 4S trial 20 mg simvastatin daily lowered total serum 
cholesterol, on average, with 25% to 28% and LDL with 
35% to 38% (1994). The HPS study (HPSCG 2002) showed 
a reduction in cardiovascular disease by 25% in individuals 
allocated to 40 mg simvastatin daily in comparison with the 
placebo group. Because one-sixth of the patients in the statin 
group in the HPS (HPSCG 2002) trial terminated their statin 
therapy, the potential reduction is probably underestimated. 
The average reduction in LDL cholesterol was 1.0 mmol/l, 
but this difference should probably also have been greater 
and has been estimated at 1.5 mmol/l (HPSCG 2002). Among 
the patients in the present study mean serum cholesterol 
decreased from about 6 mmol/l in both men and women to 
4.31 and 5.13 mmol/l in men and women, respectively, cor-
responding to what might have been expected in the men, 
but less than that in women. However, the decrease in total 
serum cholesterol may also partly be attributed to popula-
tion trends, with decreasing total serum cholesterol in the 
Göteborg population (Wilhelmsen et al 1997; Berg et al 
2005) and elsewhere (Evans et al 2001). This decrease is 
probably partly attributable to diet changes in the population 
(Becker and Pearson 2002), which include less saturated fat 
and more fruit and vegetables. Women with a ﬁ  rst AMI had 
higher mean levels of total serum cholesterol at the end of 
the study. This ﬁ  nding is explained by the fact that a higher 
proportion of women had less than the recommended dose 
of statin. In our study 20% (n = 20) of all patients had less 
than 40 mg simvastatin in the last year of the study; 18% of 
all men and 30% of all women.
A decrease in mean serum triglycerides was also observed 
(from 2.55 and 2.16 mmol/l in 1994 to 1.72 and 1.77 mmol/l 
in 2002 in men and women, respectively). Although there is 
no target level for serum triglycerides in the current European 
guidelines (De Backer et al 2003), it is known to be an important 
risk factor, particularly in women (Sharrett et al 2001). In the 
deﬁ  nition from the US National Cholesterol Education program 
serum triglycerides 1.7 mmol/l are one of the criteria for the 
metabolic syndrome. Even though the target for lipid-lowering 
treatment is serum LDL cholesterol concentrations, triglyceride 
levels are also affected by statin treatment (Anonymous 1994). 
The increasing use of lipid-lowering drugs probably explains 
why serum triglycerides have decreased despite increasing 
BMI levels. In our population about two thirds of the men and 
women with a ﬁ  rst AMI were overweight.
Despite widespread treatment with statins, a substantial 
proportion of the patients did not reach target levels for 
serum cholesterol. Target levels for total serum cholesterol 
(4.5 mmol/l) were met in 54% of the men and in 35% of 
the women. Of the 98 patients discharged after a ﬁ  rst AMI 
in 2002, 79 had simvastatin, 10 had atorvastatin, ﬂ  uvastatin, 
or pravastatin. Cholestipol hydrochloride was used in one 
patient. No patients took nicotinic acid or ﬁ  brates. Eight 
patients had no lipid-lowering medication at all. Of those 
treated with simvastatin, 13 had 20 mg daily. Fiftyﬁ  ve per 
cent of patients on the recommended dosage (40 mg daily) 
according to the HPS study (HPSCG 2002) (36/66 patients) 
reached the desired levels of 4.5 mmol/l for total serum 
cholesterol.
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Figure 3 Mean serum triglycerides in men and women at 3-months follow-up after hospitalization for ﬁ  rst myocardial infarction during 1994–2002.Vascular Health and Risk Management 2007:3(6) 1050
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During the last decades both CHD mortality and incidence 
rate of ﬁ  rst myocardial infarction have decreased (Abildstrom 
et al 2003). The decrease started before this study and con-
tinued through and after the study period. However, the use 
of statins has probably inﬂ  uenced this according to evidence 
given in prior trials (Anonymous 1994; HPSCG 2002). We 
have not investigated to which extent in this survey.
Limitations
There are several limitations of the present study. First, it is 
a single-centre study and thus data may not be representa-
tive. However, data from the Swedish National Register 
of Information and Knowledge about Heart Intensive Care 
Admission (RIKS-HIA) show that there has been a similar 
increase in usage of lipid-lowering drugs in patients below 
the age of 80 years from 12% in 1995 to 82% in 2004. The 
data in this register derive not only from university (teach-
ing) and regional hospitals but also from smaller hospitals, 
an observation that may explain the slightly higher propor-
tion of patients treated with statins in our hospital. In addi-
tion, our study only included younger patients (ie, less than 
65 years of age). Accordingly, our population is probably 
representative of Swedish AMI patients at large. Second, 
although dieticians and nurses routinely offered dietary 
counselling to all patients, systematic information regard-
ing participation and compliance was not collected, and 
hence dietary factors on possible inﬂ  uences of serum lipids 
cannot be gauged. Third, there is only information on total 
cholesterol and not LDL cholesterol because high-density 
lipoprotein cholesterol (HDL) measurements were not done 
for most of the study period. Fourth, the study was limited 
to patients discharged from the CCU and step-down unit, 
and accordingly, we have no information for those patients 
treated in other units. Presumably, this subset of patients had 
less severe manifestations of AMI, but to which extent the 
inclusion of these subjects would have affected the overall 
results is not known.
Conclusions
Since the results of the 4S study were presented in 1994 
until the end of 2002, there has been an increasing use of 
lipid-lowering medication in AMI patients, with over 80% 
nationwide now being treated. Almost all patients in the 
present study under 65 years of age with a ﬁ  rst AMI were 
treated with lipid-lowering drugs by the end of the study 
period. Despite this, target levels for serum cholesterol were 
not met in a substantial proportion of patients. These results 
imply that a standard dose of a statin may not be sufﬁ  cient and 
that younger men and women with AMI should be targeted 
for more intense lifestyle intervention. Moreover, additional 
medication may be needed.
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